A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
Michele De Tursi(University of Chieti-Pescara), Silvia Iacobelli, Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Consiglia Carella(University of Chieti-Pescara), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Cinzia Orlandini(Azienda Ospedaliera Universitaria Pisana), Enrico Ricevuto(University of L'Aquila), PierFranco Conte(University of Padua)
Cited by 2
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k